Kongressdetails

SMi Group

Contact: Pav Solanki

psolanki@smi-online.co.uk

+442078276048

SMi is delighted to announce its 2nd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 21st - 22nd May 2018.

The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs.

However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions.

This conference will cover many important and in-demand aspects of the HPAPI industry, creating a networking platform for industry professionals and key players to share their knowledge and find new innovative solutions.

Network and learn from leading professionals such as:

CHAIR FOR 2018:

Justin Mason-Home, Director, HPAPI Project Services Limited

KEY SPEAKERS INCLUDE:

Ildiko Zeigler, Validation Expert, Gedeon Richter

Ulrich Ruemenapp, Head of Launch Preparation and Coordination, Bayer

Vincenzo De Sio, HPAPI Specialist, Cristalia

Pascal Drago, Principal Technical Manager, Roche

Henri Motte, Head of Pilot Plant, UCB Pharma

Jeff Parry, Senior Scientist Manufacturability, AstraZeneca

Greg Sowell, Principal Scientific Manager, Genentech

FEATURED HIGHLIGHTS:

Discover practical approaches to HPAPI manufacturing in a controlled and efficient manner

Explore different containment methods and learn about which strategy best suits your needs

Evaluate the use of containment risk mitigation tools in early phase development

Learn how to manage and effectively and safely dispose of HPAPI, post-production waste

Discuss the most important regulations surrounding potent ingredients

View the full agenda: www.highlypotentapi.com/evvnt